-5%
Beclometasone dipropionate exhibits potent anti-inflammatory and vasoconstrictive effects within the airways. Although the precise mechanism of action is not fully established, corticosteroids are known to suppress inflammation by acting on multiple inflammatory cells (including mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and inflammatory mediators such as histamine, leukotrienes, cytokines, and eicosanoids.
Beclometasone dipropionate functions as a prodrug with low affinity for glucocorticoid receptors. It is rapidly converted by esterase enzymes into its active metabolite, beclometasone-17-monopropionate (B-17-MP), which possesses strong topical anti-inflammatory activity within the lungs. Clinical studies have demonstrated no histopathological changes in nasal mucosa following intranasal administration.
Decomit Inhaler (Beclometasone Dipropionate) is indicated for the prophylactic management of asthma of mild, moderate, or severe intensity in adults and children. When administered by inhalation, beclometasone dipropionate provides preventive anti-inflammatory therapy, offering effective control of airway inflammation with fewer and less severe systemic adverse effects compared to orally administered corticosteroids.
Mild asthma: Patients requiring regular use of symptomatic bronchodilator therapy
Moderate asthma: Patients with unstable or worsening symptoms despite bronchodilator therapy alone or ongoing prophylactic treatment
Severe asthma: Patients with chronic severe asthma who require systemic corticosteroids for symptom control; many such patients may significantly reduce or discontinue oral corticosteroids after transitioning to high-dose inhaled beclometasone dipropionate